SCHEDULE 13G/A: Great Point Partners and Affiliates Disclose 9.99% Stake in Unicycive Therapeutics

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, have disclosed a combined beneficial ownership of 9.99% of Unicycive Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl collectively reported beneficial ownership of 11,473,166 shares of Unicycive Therapeutics, Inc. common stock.
• This ownership represents 9.99% of the company's outstanding common stock.
• The reported stake includes 10,980,000 shares of Common Stock held outright by Biomedical Value Fund, L.P. (BVF) and Biomedical Offshore Value Fund, Ltd. (BOVF).
• Additionally, 493,166 shares are beneficially owned from Preferred Stock convertible into Common Stock, subject to a 9.99% beneficial ownership cap.
• The calculation of the percentage of class is based on a total of 114,353,347 shares outstanding as of January 10, 2025, plus the 493,166 convertible shares.
• Dr. Jeffrey R. Jay, M.D., as Senior Managing Member of Great Point, and Ms. Lillian Nordahl, as Managing Director of Great Point, have shared voting and investment power over these shares.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.

Risks

• The reporting persons hold Preferred Stock convertible into an additional 3,000,000 shares of Common Stock, but a 'Beneficial Ownership Cap' restricts conversion to the extent that the holder and its affiliates would beneficially own in excess of 9.99% of the outstanding Common Stock. This limits the immediate ability of the reporting persons to increase their stake beyond 9.99% through conversion.

Future Outlook

This document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance regarding the company's operations or financial performance.

Industry Context

This filing indicates a significant institutional investment in Unicycive Therapeutics, a company in the biotechnology/healthcare sector. Such Schedule 13G filings are standard disclosures for investment firms acquiring substantial, but typically non-controlling, passive stakes in publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can signal confidence or a long-term holding strategy. The beneficial ownership cap on Preferred Stock conversion prevents immediate significant dilution from this specific investor group.

Key Dates

Keywords

Unicycive Therapeutics, Great Point Partners, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investor, healthcare, biotechnology